Kate Broderick, senior vice-president of research and development at Inovio, said: "Once China had provided the DNA sequence of this virus, we were able to put it through our lab's computer technology and design a vaccine within three hours. "Our DNA medicine vaccines are novel in that they use DNA sequences from the virus to target specific parts of the pathogen which we believe the body will mount the strongest response to. PLYMOUTH MEETING, Pa., Jan. 30, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected thousands more in China to date. Inovio recently announced that it is developing INO-4800 through Phase 1 human testing in the U.S. to evaluate safety and immunogenicity with the support of an initial grant up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI). Inovio plans to rapidly develop INO-4800 against the new coronavirus and has already started preclinical testing and preparations for clinical product manufacturing. The goal of this collaboration is to leverage Advaccine's expertise to run a Phase 1 trial in China in parallel with Inovio's clinical development efforts in the U.S. Inovio and Advaccine will also work together to attract additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of future testing of INO-4800. https://www.prnewswire.com/news-rel...ainst-new-coronavirus-in-china-300995916.html
It seems this press release came out at 6am before market opened on Jan 30, so we've already had whole day of trading and it didn't move up much?
A lot of BUTS, Animal Trials to the Summer, then Human, hoping they'll have to available for end of the year, but then time to ramp up production and make 7Billion. 50/50 at best that it'll work.